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Objective: To review the impact of management changes on the early outcomes of
end-stage dilated cardiomyopathy in children.
Methods: We conducted a retrospective study of all consecutive children with
end-stage dilated cardiomyopathy who received hospital treatment since 1992. Over
the past 3 years the following management changes were made: (1) more aggressive
use of mechanical cardiac assistance; (2) high priority listing for transplantation; and
(3) ABO incompatible transplants for infants. Outcomes for 46 patients admitted
between 1992 and 1999 (group I) were compared with 53 patients between 2000 and
March 2003 (group II).
Results: In group I, 12 (26%) patients received mechanical support with recovery in
3 and transplantation in 5 (1 died). In group II, 19 (36%) patients received
extracorporeal membrane oxygenation, with recovery in 5 and transplantation in 12
(all survived). The use of mechanical assistance was associated with high morbidity
related to bleeding, end-organ failure, and long-term mechanical ventilation. Five
patients in group II received ABO incompatible transplants and all survived. There
have been no episodes of rejection or need for increased immunosuppressive
therapy. Hospital mortality has been significantly reduced (group I, 37% vs group II,
11%; P  .05).
Conclusions: Recent refinements in the management of end-stage dilated cardio-
myopathy in children have significantly reduced early mortality. Identification of
markers of early myocardial recovery and development of mechanical devices for
longer term and more physiologic support are essential to achieve further improve-
ments in outcome.
Cardiac transplantation is still the only definitive treatment availablefor end-stage dilated cardiomyopathy (EDCM) in children, anddonor organ availability remains an important limiting factor. Arecent audit of the UK Pediatric Transplant Database, however,revealed that this was not due to an absolute shortage of donororgans but to a mismatch between timing of availability of the
donor heart and recipient demand.1 Thus, in 1996/1997, 20 children died on the
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waiting list for cardiac transplantation, while during the
same period 59 pediatric hearts were not used because no
suitable recipient was available. It was hypothesized that if
the 20 patients could have been kept alive until the next
suitable unused heart became available, all but 2 could have
had transplantation within a median time of 63 days, and in
3 patients the waiting time would have been less than 1
week. To make more effective use of the donor pool, a
program for mechanical cardiac assistance as a bridge to
transplantation was initiated in 1998. This program was
approved by the Research Ethics Committee of the Institute
of Child Health/Great Ormond Street Hospital for Children
National Health Service (NHS) Trust.
Great Ormond Street Hospital for Children NHS Trust is
a supraregional center for extracorporeal membrane oxy-
genation (ECMO), and because of this experience ECMO
was used to bridge the initial patients. However, since the
time on mechanical support was estimated (1998) to last up
to several months, we moved to paracorporeal ventricular
assist devices (VADs) with the expectation that this would
allow cardiac support with recovery of end-organ function
outside intensive care.2 Unfortunately, patients with a VAD
remained dependent on mechanical ventilation and inotro-
pic agents and had significant complications. We therefore
changed back to ECMO (1999), which has been used ex-
clusively for the past 3 years.
In 2000, all transplant centers in the United Kingdom
agreed on high priority listing for patients in urgent need of
transplantation (equivalent to United Network for Organ
Sharing [UNOS] status 1A), including children on mechan-
ical cardiac support. Each of the two United Kingdom
pediatric transplant centers can only list one priority patient
at any one time, and the first compatible organ is offered to
this patient.
More recently, following the pioneering work of the
Toronto group,3 we started to perform heart transplantations
with ABO-incompatible donors. ABO-incompatible trans-
plants can be performed without the occurrence of hyper-
acute rejection in young children, because they do not yet
produce antibodies to major blood group antigens. We con-
sidered children less than 18 months for ABO-incompatible
transplant if anti-A or anti-B isohemagglutinin titers were
1:16 or less.
This article reviews the impact of these recent changes
(since 2000) on the early outcome of EDCM in children in
our institution.
Patients and Methods
Patients
The records of all patients with EDCM treated under our care
between January 1, 1992, and March 31, 2003, were reviewed. The
definition of EDCM in children was patients younger than 16 years
with dilated cardiomyopathy requiring hospital admission with
inotropic support with or without mechanical support.
Patients were divided into 2 groups: Group I (patients before
the management changes, January 1992 to December 1999) in-
cluded 46 children aged between 1 month and 16.1 years (median
2.1 years). Group II (after the management changes, January 2000
to March 2003) included 53 children aged between 7 days and 16.0
years (median 2.0 years).
Indication for Use of Mechanical Support
Mechanical bridging to transplantation was considered in patients
with EDCM who showed hemodynamic deterioration with inotro-
pic support, with or without mechanical ventilation. Children less
than 1 year old were not considered for bridge to transplantation
because the scarcity of small donor hearts in the United Kingdom
made it unlikely that an organ would be available during the period
on mechanical support. However, if recovery of cardiac function
was thought possible, mechanical bridging to recovery was con-
sidered. Severe neurologic injury and parental refusal were also
contraindications for mechanical support.
The timing of initiating mechanical support is difficult in pa-
tients with severe heart failure who sometimes decompensate
suddenly. Patients were therefore closely observed in the high
dependency unit for signs of deteriorating renal, hepatic, and
gastrointestinal function, alteration of mental state, or poor periph-
eral perfusion. Other indications for ECMO included the develop-
ment of cardiac arrhythmias and escalating inotropic requirement.
Sixty-six percent of patients received a minimum of 2 inotropic
agents. Pulmonary artery catheters were not used to assess cardiac
performance. More recently, we had a clear-fluid primed ECMO
circuit on standby so that in case of cardiac deterioration ECMO
could be instituted immediately.
Mechanical Assist Devices
ECMO. A standardized ECMO circuit including a roller pump
and appropriately sized tubing and cannulas for patient weight was
used. ECMO cannulation was routinely performed on the intensive
care unit and typically involved open cannulation of the right
common carotid artery and internal jugular vein through a 2 to
3-cm skin crease incision in the neck. In patients over 10 kg,
additional venous drainage was often necessary, and a venous
cannula was placed in a femoral vein by a percutaneous Seldinger
technique. ECMO was initially commenced aiming at pump flows
of at least 100% of calculated resting cardiac output for body size
and adjusted according to body perfusion, arterial oxygenation,
and mixed venous oxygenation. Inotropic agents were weaned as
tolerated and hypertension was treated with vasodilators. If renal
support was required, a hemofilter was built into the ECMO
circuit. Decompression of the left side of the heart was routine and
performed by balloon or blade septostomy under fluoroscopy and
ultrasound guidance in the catheter laboratory, usually within 24
hours of initiating ECMO. Patients were nursed sedated and ven-
tilated on the intensive care unit. Anticoagulation for ECMO
consisted of intravenous heparin 5 to 25 U · kg1 · h1 maintain-
ing an activated clotting time between 160 and 180 seconds.
VAD. The Medos-HIA VAD (Stolberg, Germany) is a para-
corporeal and pneumatically driven device that is available in a
range of sizes of pumping chambers and cannulas. Left ventricular
assist devices (LVAD) range from 10 mL stroke volume for
infants to 80 mL for adults, with 10% reduced volume for right
ventricular support. Device placement was carried out in the op-
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erating theater via median sternotomy and on cardiopulmonary
bypass (CPB). For placement of the LVAD, the left atrium was
cannulated for device inflow and the ascending aorta for outflow.
RVAD cannulation was via the right atrium and pulmonary artery.
After device placement, CPB was discontinued with reversal of
heparin and transfusion of blood products as necessary to achieve
a normal coagulation profile. Intravenous heparin was commenced
after 4 hours aiming at an activated clotting time of 160 to 180
seconds.
Mechanical circulatory support was used in 12 of 46 (26%)
patients in group I and in 19 of 53 (36%) patients in group II. The
devices used for assistance are summarized in Table 1. Between
September 1998 and July 1999, 4 patients were supported on the
Medos-HIA. One patient received an LVAD, and in the remaining
3 patients, both ventricles were supported (BIVAD). A further
patient was placed on a Berlin Heart BIVAD (Berlin Heart, Berlin,
Germany) in another institution by the Great Ormond Street team
and then referred to our institution. The Berlin Heart operates
along the same principles as the Medos-HIA VAD. The remaining
patients all received ECMO.
ABO-Incompatible Transplantation
We followed the guidelines for ABO-incompatible transplantation
previously described by West and coworkers.3 In short, patients
underwent standard blood typing, and serum was tested for anti-A
and anti-B antibodies with standard agglutination tests with eryth-
rocytes from a known blood type. The blood type of the donor was
obtained via the transplant coordinator. All cellular blood products
given during or after transplantation were either blood type O
(which contains no A or B antigens) or the recipient’s blood type.
All plasma products were type AB (or the donor’s blood type if the
recipient was type O) and therefore had few or no exogenous
anti-A or anti-B antibodies. Platelets were donor group A or B type
specific, as type AB is not available in the United Kingdom. At the
initiation of CPB, exchange transfusion was performed, up to 3
times the estimated circulating blood volume of the recipient.
Blood was drained via the venous limb of the bypass circuit and
replaced with an equal volume of bank blood and plasma from
type AB blood. Discarded blood was separated into plasma and
red-cell fractions with a commercial cell salvage system, the
plasma was discarded, and the red cells were returned to the
patient.
Results
Outcome After Mechanical Support
The outcomes of the 31 patients who received mechanical
assistance for EDCM are given in Table 2. Three patients
(25%) in group I and 5 (26%) in group II showed improve-
ment of myocardial function on echocardiography within 48
hours and were successfully weaned from support. Seven of
8 (87.5%) patients bridged to recovery are alive at follow-up
from 5 to 81.5 months (23 months). One patient died sud-
denly at home after 19 months. One patient in group II with
Epstein-Barr viral myocarditis had a further episode of
severe heart failure 20 months later. He had a second
ECMO run followed by successful cardiac transplantation.
This patient appears in the statistics twice.
Five (42%) patients in group I and 12 (63%) in group II
underwent cardiac transplantation. The patient on the Berlin
Heart underwent successful transplantation on day 5 by the
Great Ormond Street Hospital team at the referring hospital
and was subsequently transferred to our institution for post-
operative care. There was 1 hospital death. Acute respira-
tory distress syndrome developed in a patient in group I and
necessitated posttransplant ECMO. She died of multiorgan
failure 8 days after cardiac transplantation. There was 1 late
death at 50 months from rejection related to noncompliance
with medication. The long-term survivors have now been
observed for 5 weeks to 108 months (17 months).
Mechanical support was withdrawn in 4 patients in group
I. Large cerebral infarcts developed in 2 patients during
support on the Medos VAD. Multiorgan failure developed
in 2 patients on ECMO, including 1 in whom the parents
declined transplantation and requested withdrawal of me-
chanical support. ECMO support was withdrawn in 2 pa-
tients in group II. One patient had severe neurologic injury
and renal failure. He had been ventilated for 4 days before
ECMO and required cardiopulmonary resuscitation 24
hours before ECMO was commenced. The other patient was
a 7-day-old child with cardiorespiratory collapse who was
placed on ECMO as a bridge to recovery. A diagnosis of
enteroviral myocarditis was made. Progressive multiorgan
failure developed and, in agreement with the parents, sup-
port was withdrawn on day 8.
The use of mechanical cardiac assistance was associated
with a large number of complications. The 4 patients on the
Medos VAD all required reexploration for bleeding and
tamponade and had ongoing requirements for inotropic sup-
port and mechanical ventilation. Two had irreversible brain
TABLE 1. Mechanical cardiac support
Group I:
12 patients
Group II:
19 patients
Age 1.8 y–16.1 y (10.0 y) 7 d–16.0 y (3.9 y)
VAD 5 0
ECMO 7 19
VAD, Ventricular assist device; ECMO, extracorporeal membrane oxygen-
ation.
TABLE 2. Outcomes following mechanical cardiac support
Group I (12 patients) Group II (19 patients)
No. of
patients
Days on
support
No. of
patients
Days on
support
Recovery 3 4–10 (7) 5 6–12 (9)
Transplant 5 0.5–9 (6) 12 2–21 (7)
Support withdrawn 4 7–12 (10) 2 8–11
Overall mortality 5/12 (42%) 2/19 (11%)
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injury, and renal support was required in 2 patients. In
contrast, the patient on the Berlin Heart had no severe
bleeding or renal problems. In the 26 patients who received
ECMO there were no significant bleeding problems. How-
ever, the following problems were observed: prolonged
ventilation (5 days) after transplant in 9 patients (range
7-48 days, median 24), of whom 6 required a tracheostomy;
renal failure necessitating peritoneal dialysis or hemofiltra-
tion (10 patients); medical treatment for withdrawal of
sedation (8 patients); and resolving right hemiparesis (1
patient).
High Priority Listing for Transplantation
Nineteen patients in group II were put on the high priority
list, including 11 of 12 ECMO patients (Table 3). One
ECMO patient could not be listed because another patient
had already been priority listed. Fifteen patients had trans-
plants and all survived. The 4 patients who died included a
7-month old child who had an acute respiratory arrest after
waiting for 39 days. Two patients had cardiac arrest on days
6 and 10, respectively. Multiorgan failure developed in 1
patient 3 days after listing; the parents requested no further
active intervention.
ABO Incompatible Transplantation
Six patients were listed for ABO mismatch transplantation,
2 of whom were high priority listed, including 1 patient on
ECMO. All had transplants. One patient with blood group A
received a compatible donor heart within 24 hours. Five
patients underwent ABO incompatible transplantation after
5 to 87 days (13 days). The blood groups of the donors and
recipients are detailed in Table 4. None of the patients had
hyperacute rejection. All survived and have now been fol-
lowed up for 2 to 20 months (5 months). The 2 patients with
detectable anti-A or anti-B antibodies before transplantation
have remained antibody-negative at most recent follow-up.
Only 1 other patient had low antibody titers (1:1) to the
incompatible graft. Maintenance immunosuppressive ther-
apy includes tacrolimus and either azathioprine or myco-
phenolate mofetil. No patient is on long-term steroids.
There have been no episodes of humoral rejection.
Table 5 summarizes the overall effect of the change in
EDCM on early outcome. In the most recent treatment
group, hospital survival has significantly improved (group I:
29/46 patients (63%) versus group II: 47/53 patients (89%),
P  .05).
Comment
Our recent experience with mechanical bridging to trans-
plantation compares favorably with the reported pediatric
literature. Kirshbom and coworkers4 reported on 31 children
who underwent bridging to cardiac transplantation with
ECMO, either because of postcardiotomy failure (17) or
cardiomyopathy, myocarditis, or other reasons (14). Six
were weaned and survived to discharge and 12 went on to
transplantation. The authors did not comment on hospital
survival but reported 83% survival at 1 year. More recently,
Gajarski and associates5 published a series of 145 children
supported on ECMO, 21 of whom were listed for transplan-
tation. The diagnosis was postcardiotomy failure in 17,
myocarditis in 2, and myopathy in a further 2 patients.
Twelve patients underwent transplantation and 10 survived
to discharge.
Despite excellent survival after bridging in our patients,
a large number of difficulties remain associated with me-
chanical cardiac assistance in children. In patients supported
with the Medos VAD who underwent cannulation on CPB,
bleeding was a major problem. Furthermore, the cerebral
infarcts were a cause for concern. Interestingly, the single
patient supported with the Berlin Heart had no bleeding or
neurologic problems. In the ECMO group who underwent
TABLE 4. ABO mismatch transplant: Donor and recipient
blood groups.
Recipient blood group Donor blood group
B A
O A
A AB
A AB
O A
TABLE 5. Effect of management strategy on hospital sur-
vival for end-stage dilated cardiomyopathy in children
Group I Group II
No. of
patients
No.
died
No. of
patients
No.
died
Medical
therapy
Medical treatment
only
20 11 16 4
Transplant 14 1 18 0
Mechanical
support
Recovery 3 0 5 0
Transplant 5 1 12 0
Support withdrawn 4 4 2 2
Total 46 17* (37%) 53 6* (11%)
*P  .05.
TABLE 3. Outcomes following high priority listing
Pre-transplant
support No. of patients
Days on high
priority list Outcome
Medical treatment 8 3–39 (6) Died 4
Transplant 4
ECMO 11 2–21 (6) Transplant 11
Fifteen of 19 (79%) were offered organs. All survived. ECMO, Extracorpo-
real membrane oxygenation.
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peripheral cannulation, bleeding was not a problem. How-
ever, there was important morbidity related to inadequate
end-organ perfusion and prolonged sedation and mechanical
ventilation. We are currently addressing these problems. In
the initial phase of the ECMO run we try to optimize
off-loading of the heart by paying particular attention to
cannula position and decompression of the left side of the
heart with early septostomy. We now also try to avoid the
complications associated with long-term intensive care such
as sedation withdrawal and weakness. Muscle paralysis is
avoided whenever possible. Patients are kept comfortable
with a morphine infusion of 10 to 40 g · kg1 · h1 and,
if required, midazolam 1 to 4 g · kg1 · min1. Analgesia
and sedation are titrated clinically to the lowest dose that
keeps the patient awake but comfortable.
The development of mechanical assist devices for chil-
dren continues to lag far behind that for the adult popula-
tion, where out-of-hospital support with preservation of
end-organ function can be achieved6 and sometimes even
destination therapy.7 Although children can in principle
benefit from the same technological advances, there are the
additional challenges related to small size. Perhaps more
importantly, pediatric VADs have generated little commer-
cial interest because the market is small but paradoxically a
large range of device sizes is required.
The use of intra-aortic balloon pump (IABP) counterpul-
sation is a less invasive mode of support. Although widely
used in the adult population, its application has been limited
in children. In a study by Hawkins and colleagues,8 22
patients received an IABP over a 10-year period with a 59%
survival, and over a similar time period Pennington9 re-
ported on 38 patients with a 37% survival. In children,
effective IABP is difficult because of the rapid heart rate.
Moreover, the compliance of the aortic wall may result in
only slight diastolic augmentation. The small-sized vessels
make IABP insertion difficult with high risk of limb isch-
emia, especially in a low cardiac output state.
There are currently very few prognostic indicators for
recovery of myocardial function. Our decision to bridge to
recovery is guided mainly by improvement of cardiac func-
tion on serial echocardiography during the first few days of
mechanical cardiac assistance. The underlying diagnosis
may aid the decision making. All patients who were suc-
cessfully weaned had viral myocarditis. None of the patients
with familial dilated cardiomyopathy could be weaned. The
problem is that in several patients the diagnosis was not
confirmed until some weeks later. Because the time of
successful mechanical support is limited to a few weeks, we
have a policy of early listing for transplantation. We ac-
knowledge that with this aggressive strategy, some patients
may receive cardiac transplantation who could possibly
have been bridged to recovery. The other issue is whether
the strategy of early high priority listing would disadvantage
other patients on the normal transplant waiting list. A recent
audit of the United Kingdom pediatric transplant activity
has shown that this is not the case.10 Despite this, it is of
paramount importance that early indicators of myocardial
recovery become available. The use of tissue Doppler im-
aging as a load-independent assessment of myocardial func-
tion may hold some promise for the future.11
The introduction of ABO mismatch transplantation has
improved the efficiency of use of the donor pool. The exact
indications for ABO-incompatible transplantation are still
evolving, but we currently believe that infants with antibody
titers up to 1:16 can be considered for a mismatch cardiac
transplant. The long-term effects of this strategy will only
become apparent over time with the maturation of the
immune system of the recipients.
Conclusions
Recent refinements in the management of EDCM in chil-
dren have significantly reduced early mortality. The timing
for initiating mechanical support remains difficult. With the
limitations of currently available pediatric devices, the du-
ration of successful support is limited and unnecessary
ECMO runs should be avoided. Areas for future research
and development include identification of markers of myo-
cardial recovery and the development of mechanical devices
for longer term and more physiologic support.
We are grateful to Susan Francis for her commitment, which
greatly facilitated the preparation of this manuscript. We thank
Lucy Robinson, Jonathan Senior, and Faith Hanstater for their
assistance. UK Transplant contributed to the data in this paper.
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Discussion
Dr Charles B. Huddleston (St Louis, Mo). We generally hope
that 50% of patients who require mechanical support will be able
to leave the hospital. Your results are obviously much better than
that.
There is quite a difference in the presentation and in the
manuscript that I received from the abstract that is printed in the
program, and it deals with the group I patients. Please comment on
what prompted the difference in terms of going back earlier in the
time frame in that particular group.
Dr McMahon. Initially we intended to look at a 5-year retro-
spective study, and then we decided to evaluate 10 years to have
a more relevant group.
Dr C. Huddleston. The abstract was accepted on the program
with a smaller group. I thought it might be easier too. But that is
not important.
Dr McMahon. One of our cardiologists was very keen to look
at a decade’s worth of treatment.
Dr Huddleston. The hard part with these patients is identifying
the ones that are going to get into big trouble or have an arrest
before receiving an organ. It is all well and good to have a priority
listing established, but I find it extremely difficult to predict those
who are going to just teeter on the edge of inotropic support until
they get an organ and those who do go on to arrest.
Did you use anything specifically to identify those who were
worsening? The manuscript merely includes a comment about
those who had hemodynamic deterioration. Were you monitoring
them with pulmonary artery catheters, for instance, or any other
manipulations in the intensive care unit that really established the
presence of a hemodynamic decline?
Having said that, the manuscript seems to indicate that a
number of patients did have an episode of cardiopulmonary resus-
citation before going on to some sort of mechanical support.
Therefore, it was hard for me to tease out that there really was an
institution of earlier mechanical support in this second group
without there being some objective criteria used in that group to
signal the time to go on to support. I find this an extremely difficult
issue in our own patient population.
Dr McMahon. Thank you for your comments.
In relation to the question regarding mechanical support and
criteria for either being on mechanical support or deteriorating, I
think generally everyone finds it very difficult.
With increasing experience within the entire unit, our prefer-
ence is to keep the patients in house rather than in the referring
center, so that they can be monitored for the development of
arrhythmias that may further decompensate their heart failure and
so that their increasing inotropic requirement can be monitored.
Despite the earlier institution of ECMO in group II, there were
a total of 9 patients who had cardiopulmonary resuscitation before
ECMO; 4 of them had ventricular tachycardia or a ventricular
fibrillatory arrest and 5 had an asystolic arrest.
Even within group II, this is work in process. There were 4
patients who died early in 2000 who would probably have now
been kept in house so that mechanical support could have been
instituted earlier. I think everyone finds objective criteria quite
difficult to pin down.
With regard to your last question about the high priority listing,
generally transplantation units within the United Kingdom work
together very well. I think the difficulty would be with teenagers
who would compete possibly with young adults on the list.
If both pediatric units had a patient on a high priority list, the
organ would be offered to the first listed, compatible recipient.
However, the units would discuss with each other to decide which
of their competing patients was the sickest and generally agree to
give the organ to the patient with the highest need. We are proud
of the good cooperation between the units in that regard.
Dr Florentino J. Vargas (Buenos Aires, Argentina). Congrat-
ulations for your results. Considering how aggressive you have
been with the ABO mismatch, I suppose that you have done
something similar regarding weight or size mismatch.
In the pediatric population, in the presence of donor shortage,
some groups, including our group, agree to take some significant
weight mismatch. We have allowed a weight difference of as much
as three times between donor and recipient. Good results were
obtained in these patients, the oldest currently being in her elev-
enth year after transplant. I know some groups would disagree with
this policy. Can you comment on that?
Dr McMahon. Thank you. Generally for heart transplants, we
accept a weight of two times above the weight of the recipient as
the donor organ, and the ABO mismatch transplantation has ob-
viously come into play because of the lack of donor availability in
those patients less than 1 year.
Dr Carl L. Backer (Chicago, Ill). In our series of transplan-
tation, we have had a similar improvement in our results.
One of the things that we changed, which I think has helped
significantly, is converting from the right atrial technique at the
time of the surgical implant to a bicaval technique. At least in our
review, that has improved significantly the outcome of our pa-
tients. Have you had any change in your surgical technique while
treating that cohort.
Dr McMahon. I think I would like to defer that to my senior
surgical colleague.
Mr Marc R. de Leval (London, United Kingdom). We have
changed to the bicaval technique as well, but much before the
change of the management protocol.
I perhaps could add something about medical management. We
have appointed a staff cardiologist to look after those patients, and
we now have a cardiomyopathy team, which has improved the
overall management of those patients, and this includes the timing
of putting them on mechanical support.
Dr Richard A. Jonas (Boston, Mass). I notice that you are
using ECMO now as your preferred method of mechanical sup-
port. How do you decide to decompress the left heart and how you
actually do that?
Mr de Leval. All these patients on ECMO undergo a decom-
pression of the left heart, which is done either by blade septectomy
or balloon septostomy after perforation of the atrial septum.
Dr Jonas. Do they go to the catheterization laboratory after
being put on ECMO?
Mr de Leval. Yes.
Dr Jonas. Am I correct that you do not leave the catheter in?
Do you simply make a septostomy or septectomy and allow
left-to-right decompression through the atrial septum?
Mr de Leval. That’s right.
Dr Jonas. So you are just doing it in everybody?
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Mr de Leval. Yes. That’s our protocol; if they are put on
ECMO, they have a septectomy.
Dr Carlos J. Troconis (Caracas, Venezuela). In your presen-
tation you pointed out that some of these adults who are connected
to VADs or any type of assist device on the left side, at early time,
substantially improved and were able to go home, as their status
improved from the high priority listing.
Do you think if you approach those babies with DCM in early
timing, using a better LVAD, their conditions might improve from
the high priority listing, following the same track as in the adults
group?
Dr McMahon. I think that was the expectation when the VADs
were introduced in the late 1990s, and unfortunately, a high
morbidity was encountered. It was just not deemed possible for the
program to continue.
That is the overall aim. I would hope that VADs can be
produced to allow children to recover with the aid of a VAD
outside the intensive care unit.
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